120 related articles for article (PubMed ID: 7540165)
21. Lymph node metastasis: ultrasmall superparamagnetic iron oxide-enhanced MR imaging versus PET/CT in a rabbit model.
Choi SH; Moon WK; Hong JH; Son KR; Cho N; Kwon BJ; Lee JJ; Chung JK; Min HS; Park SH
Radiology; 2007 Jan; 242(1):137-43. PubMed ID: 17090719
[TBL] [Abstract][Full Text] [Related]
22. Axillary lymph node metastases in patients with breast carcinomas: assessment with nonenhanced versus uspio-enhanced MR imaging.
Memarsadeghi M; Riedl CC; Kaneider A; Galid A; Rudas M; Matzek W; Helbich TH
Radiology; 2006 Nov; 241(2):367-77. PubMed ID: 17057065
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of an ultrasmall superparamagnetic iron oxide in MRI in a bone tumor model in rabbits.
Bush CH; Mladinich CR; Montgomery WJ
J Magn Reson Imaging; 1997; 7(3):579-84. PubMed ID: 9170045
[TBL] [Abstract][Full Text] [Related]
24. Rectal cancer: mesorectal lymph nodes at MR imaging with USPIO versus histopathologic findings--initial observations.
Koh DM; Brown G; Temple L; Raja A; Toomey P; Bett N; Norman AR; Husband JE
Radiology; 2004 Apr; 231(1):91-9. PubMed ID: 14976266
[TBL] [Abstract][Full Text] [Related]
25. Histochemical detection of ultrasmall superparamagnetic iron oxide (USPIO) contrast medium uptake in experimental brain ischemia.
Schroeter M; Saleh A; Wiedermann D; Hoehn M; Jander S
Magn Reson Med; 2004 Aug; 52(2):403-6. PubMed ID: 15282824
[TBL] [Abstract][Full Text] [Related]
26. MR lymphography with superparamagnetic iron nanoparticles in rats: pathologic basis for contrast enhancement.
Guimaraes R; Clément O; Bittoun J; Carnot F; Frija G
AJR Am J Roentgenol; 1994 Jan; 162(1):201-7. PubMed ID: 8273666
[TBL] [Abstract][Full Text] [Related]
27. Biodistribution of ultrasmall iron oxide particles in the rat liver.
Van Beers BE; Sempoux C; Materne R; Delos M; Smith AM
J Magn Reson Imaging; 2001 Apr; 13(4):594-9. PubMed ID: 11276104
[TBL] [Abstract][Full Text] [Related]
28. [Lymph node image with ultrasmall superparamagnetic iron oxide and comparison with pathological result].
Xue HD; Lei J; Li Z; Wang DT; Zhou WX; Dai W; Jin ZY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Apr; 31(2):139-45. PubMed ID: 19507589
[TBL] [Abstract][Full Text] [Related]
29. Interstitial MR lymphography with iron oxide particles: results in tumor-free and VX2 tumor-bearing rabbits.
Taupitz M; Wagner S; Hamm B; Binder A; Pfefferer D
AJR Am J Roentgenol; 1993 Jul; 161(1):193-200. PubMed ID: 8517301
[TBL] [Abstract][Full Text] [Related]
30. Imaging of macrophages in soft-tissue infection in rats: relationship between ultrasmall superparamagnetic iron oxide dose and MR signal characteristics.
Lutz AM; Weishaupt D; Persohn E; Goepfert K; Froehlich J; Sasse B; Gottschalk J; Marincek B; Kaim AH
Radiology; 2005 Mar; 234(3):765-75. PubMed ID: 15665219
[TBL] [Abstract][Full Text] [Related]
31. Differential uptake of ferumoxtran-10 and ferumoxytol, ultrasmall superparamagnetic iron oxide contrast agents in rabbit: critical determinants of atherosclerotic plaque labeling.
Yancy AD; Olzinski AR; Hu TC; Lenhard SC; Aravindhan K; Gruver SM; Jacobs PM; Willette RN; Jucker BM
J Magn Reson Imaging; 2005 Apr; 21(4):432-42. PubMed ID: 15779033
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of lymph node metastases of breast cancer using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging.
Harada T; Tanigawa N; Matsuki M; Nohara T; Narabayashi I
Eur J Radiol; 2007 Sep; 63(3):401-7. PubMed ID: 17398053
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of retroperitoneal and pelvic lymph node metastases with MRI and MR lymphangiography.
Bellin MF; Lebleu L; Meric JB
Abdom Imaging; 2003; 28(2):155-63. PubMed ID: 12592461
[TBL] [Abstract][Full Text] [Related]
34. MR lymphography using iron oxide particles. Detection of lymph node metastases in the VX2 rabbit tumor model.
Taupitz M; Wagner S; Hamm B; Dienemann D; Lawaczeck R; Wolf KJ
Acta Radiol; 1993 Jan; 34(1):10-5. PubMed ID: 8427741
[TBL] [Abstract][Full Text] [Related]
35. Lymph nodes: microstructural anatomy at MR imaging.
Lee AS; Weissleder R; Brady TJ; Wittenberg J
Radiology; 1991 Feb; 178(2):519-22. PubMed ID: 1987619
[TBL] [Abstract][Full Text] [Related]
36. The pharmacokinetics of the lymphotropic nanoparticle MRI contrast agent ferumoxtran-10.
Islam T; Wolf G
Cancer Biomark; 2009; 5(2):69-73. PubMed ID: 19414923
[TBL] [Abstract][Full Text] [Related]
37. MR lymphangiography using ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: radiographic-pathologic correlation.
Harisinghani MG; Saini S; Weissleder R; Hahn PF; Yantiss RK; Tempany C; Wood BJ; Mueller PR
AJR Am J Roentgenol; 1999 May; 172(5):1347-51. PubMed ID: 10227514
[TBL] [Abstract][Full Text] [Related]
38. Targeting of ultrasmall superparamagnetic iron oxide (USPIO) particles to tumor cells in vivo by using transferrin receptor pathways.
Kresse M; Wagner S; Pfefferer D; Lawaczeck R; Elste V; Semmler W
Magn Reson Med; 1998 Aug; 40(2):236-42. PubMed ID: 9702705
[TBL] [Abstract][Full Text] [Related]
39. Use of USPIO-induced magnetic susceptibility artifacts to identify sentinel lymph nodes and lymphatic drainage patterns. I. Dependence of artifact size with subcutaneous Combidex dose in rats.
Rogers JM; Jung CW; Lewis J; Groman EV
Magn Reson Imaging; 1998 Oct; 16(8):917-23. PubMed ID: 9814774
[TBL] [Abstract][Full Text] [Related]
40. Investigation of atherosclerotic plaques with MRI at 3 T using ultrasmall superparamagnetic particles of iron oxide.
Priest AN; Ittrich H; Jahntz CL; Kooijman H; Weber C; Adam G
Magn Reson Imaging; 2006 Dec; 24(10):1287-93. PubMed ID: 17145399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
